Why the study?
There is limited research on coagulation dysfunction associated with fulminant myocarditis, making rebalancing of the coagulation system a clinical challenge.
Case Report (n=1)
Comprehensive management including tailored anticoagulation and blood product supplementation successfully corrected severe coagulopathy in a patient with fulminant myocarditis and cardiogenic shock.
Answers are grounded in this paper and cite their sources.
May inform coagulopathy management in fulminant myocarditis; leaves open need for prospective validation.
Fulminant myocarditis (FM) is an acute, diffuse inflammatory myocardial disease characterized by abrupt onset and extremely rapid progression. Patients typically exhibit haemodynamic abnormalities that may lead to respiratory failure, liver and renal failure, and subsequent coagulopathy. Collectively, these complications significantly increase the risk of early mortality. Currently, there is limited research on coagulation dysfunction associated with FM; therefore, achieving a rebalancing of the coagulation system is a challenge for successful treatment. We report a case of coagulation disorder secondary to FM, in which the patient recovered successfully and was discharged following comprehensive treatment and correction of coagulation function. By analyzing the etiology of this condition and emphasizing strategies for correcting coagulation disorders, we aim to provide valuable references for clinical diagnosis and management.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2025) conducted a case report in Fulminant myocarditis with cardiogenic shock, acute liver injury, and coagulation dysfunction (n=1). Comprehensive treatment including unfractionated heparin, fresh frozen plasma, cryoprecipitate, and immunosupportive therapy was evaluated on Correction of coagulation function and clinical recovery.
Synapse has enriched 10 related papers. Consider them for comparative context: